Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Year Of Mandatory Reports Shows Safety-Monitoring Value Of AER Data

This article was originally published in The Tan Sheet

Executive Summary

The spike in dietary supplement adverse event reports in 2008 demonstrates that mandatory reporting gives FDA a more effective safety surveillance tool than voluntary reporting alone

You may also be interested in...



Hydroxycut Recall Sheds Light On Pros And Cons Of AER System

Identifying possible risks linked to dietary supplements - such as the recalled line of Hydroxycut weight-loss products - is challenging because FDA generally works with post-market information, an agency executive said

FDA Audits Of Supplement, OTC AERs Likely Starting This Year – Consultant

Dietary supplement and OTC drug companies should not become accustomed to the "honeymoon" FDA has allowed from adverse event reporting compliance audits, according to Rick Kingston, an executive with SafetyCall adverse event reporting call center

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel